Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: a retrospective study(WJOG4407GSS)
Not Applicable
- Conditions
- metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000022171
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
1.Brain metastasis with symptoms. 2.Massive asites, pleural effusion or pericardial effusion. 3.Double cancer with in five years prior to enroll in this study. 4.Serious non-healing wound. 5.Major surgical procedure within 28 days prior to enroll in this study. 6.Minor surgical procedure within 14 days prior to enroll in this study. 7.Other serious concomitant disease. 8.Regular use of corticosteroid. 9.Regular use of anticoagulation therapy. 10.Peripheral neuropathy > Grade 1 at baseline. 11.Active infectious disease. 12.History of serious hypersensitivity. 13.Hepatitis B surface antigen. 14.Mental disorder. 15.Pregnant or nursing.
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Correlation between morphologic response and progression-free survival
- Secondary Outcome Measures
Name Time Method Correlation between morphologic response and overall survival